The effect of deprenyl (selegiline) on the natural history of Parkinson's disease

Science
J W Tetrud, J W Langston

Abstract

The effects of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), a neurotoxin that produces the symptoms of Parkinson's disease, can be fully prevented in experimental animals by inhibiting monoamine oxidase B. On the basis of this observation, a double-blind, placebo-controlled study in patients with early Parkinson's disease was initiated to determine whether deprenyl (a selective monoamine oxidase B inhibitor) would delay the need for L-dopa therapy by slowing the progression of the disease. Fifty-four patients were randomly assigned to deprenyl (10 mg/day) or placebo treatment groups and followed until L-dopa therapy was indicated or until the patient had been in the study for 3 years. Analysis of Kaplan-Meier survival curves for each group showed that deprenyl delayed the need for L-dopa therapy; the average time until L-dopa was needed was 312.1 days for patients in the placebo group and 548.9 days for patients in the deprenyl group. Disease progression, as monitored by five different assessment scales, was slowed (by 40 to 83% per year) in the deprenyl group compared to placebo. Therefore, early deprenyl therapy delays the requirement for antiparkinsonian medication, possibly by slowing progression of the disease.

References

Nov 1, 1975·Journal of Psychiatric Research·M F FolsteinP R McHugh
Nov 1, 1985·Science·R Lewin
May 1, 1967·Neurology·M M Hoehn, M D Yahr
Sep 28, 1984·Science·J W LangstonL S Forno
Jan 1, 1983·Modern Problems of Pharmacopsychiatry·W BirkmayerM B Youdim
Apr 30, 1984·Biochemical and Biophysical Research Communications·K ChibaN Castagnoli

❮ Previous
Next ❯

Citations

Jun 1, 2000·Movement Disorders : Official Journal of the Movement Disorder Society·E B MontgomeryK Lyons
Apr 1, 2003·Annals of Neurology·Fabrizio Stocchi, C Warren Olanow
Apr 1, 1993·Annals of Neurology·J H KurthJ D Schwankhaus
Nov 1, 1995·Annals of Neurology·C W OlanowJ Esterlitz
Jul 1, 1997·Journal of Clinical Pharmacology·E H HeinonenR A Lammintausta
Dec 1, 1991·Journal of Neuroscience Research·W G Tatton, C E Greenwood
Feb 1, 1992·Journal of Neuroscience Research·P T Salo, W G Tatton
Jan 1, 1990·Movement Disorders : Official Journal of the Movement Disorder Society·W G JohnsonR Duvoisin
Jan 1, 1992·Movement Disorders : Official Journal of the Movement Disorder Society·J W LangstonR Watts
Jan 1, 1993·Movement Disorders : Official Journal of the Movement Disorder Society·M B YoudimP Riederer
Jan 1, 1993·Movement Disorders : Official Journal of the Movement Disorder Society·M S SandyD A Di Monte
Apr 1, 1993·Movement Disorders : Official Journal of the Movement Disorder Society·U BonuccelliA Muratorio
Jan 1, 1993·Movement Disorders : Official Journal of the Movement Disorder Society·C W Olanow
Jan 1, 1993·Movement Disorders : Official Journal of the Movement Disorder Society·K T Finnegan
Jan 1, 1993·Movement Disorders : Official Journal of the Movement Disorder Society·W G Tatton
Jan 1, 1993·Movement Disorders : Official Journal of the Movement Disorder Society·J O Rinne
Jan 1, 1993·Movement Disorders : Official Journal of the Movement Disorder Society·H AllainH C Neukirch
Jan 1, 1993·Movement Disorders : Official Journal of the Movement Disorder Society·V V MyllyläE H Heinonen
May 1, 1994·Movement Disorders : Official Journal of the Movement Disorder Society·G S HotamisligilJ Sullivan
May 1, 1995·Movement Disorders : Official Journal of the Movement Disorder Society·S PrzedborskiS Fahn
Jul 1, 1997·Movement Disorders : Official Journal of the Movement Disorder Society·J LyytinenH Teräväinen
Jan 1, 1993·Journal of Neural Transmission. General Section·W MaruyamaM Naoi
Jan 1, 1993·Journal of Neural Transmission. General Section·A M Palmer, S T DeKosky
Jan 1, 1993·Journal of Neural Transmission. General Section·C W Olanow
Jan 1, 1992·Journal of Neural Transmission. General Section·S K JohnsonG C Wagner
Jan 1, 1991·Journal of Neural Transmission. General Section·A ClowM Walker
Jan 1, 1992·Journal of Neural Transmission. General Section·A ClowD Dexter
Jan 1, 1995·Journal of Neural Transmission. General Section·A Fredriksson, T Archer
Jan 1, 1995·Journal of Neural Transmission. General Section·R M WuC C Chiueh
Jan 1, 1992·Journal of Neural Transmission. Parkinson's Disease and Dementia Section·J Málly

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.